Revive Therapeutics

Oregon Psilocybin Services Tracker: Q1 2025July 4, 2025
As the first cut of data from Oregon's psilocybin program becomes available, we take a deep dive into emerging trends through various data visualisations and analysis. This marks the first instalment of our new Oregon Psilocybin Services Tracker, which will produce analysis of each cut of data as it is released. ∎
Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of PsychedelicsJuly 3, 2025
Psychedelic Alpha’s Charles Bliss speaks with Chris Timmermann, Research Fellow in Neuroscience, Meditation and Psychedelics at University College London, about why understanding and integrating psychedelic experiences may be just as vital for personal growth as for treating mental illness.
Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing ModelJuly 1, 2025
We cover Beckley Psytech and atai Life Sciences' conference call this morning, where company executives provided further details on the Phase 2b readout of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression and took aim at their closest competitor's model.
Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b StudyJuly 1, 2025
This morning, Beckley Psytech shares topline data from its Phase 2b study of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression (TRD). The study, the largest of the drug to date, printed positive results, with a significant and rapid antidepressant effect and favourable safety profile. Here, we take a closer look at the results and share our quick-take analysis with reference to GH Research’s similar Phase 2b study.
Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 PlansJuly 1, 2025
Psychedelic Alpha’s Josh Hardman sits down with Beckley Psytech CEO Cosmo Feilding-Mellen and Chief Scientific and Medical Officer Rob Conley to discuss today’s topline results from the company’s Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression (TRD).

Revive Therapeutics

Latest News

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Ltd. Expands Life Offering to Quebec

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

Join our Newsletter

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights